COVIS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for COVIS, and when can generic versions of COVIS drugs launch?
COVIS has eleven approved drugs.
There are five US patents protecting COVIS drugs.
There are one hundred and forty-four patent family members on COVIS drugs in forty-six countries and twenty-seven supplementary protection certificates in fourteen countries.
Drugs and US Patents for COVIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Covis | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-003 | Jan 10, 2008 | RX | Yes | Yes | 8,371,292 | ⤷ Sign Up | ⤷ Sign Up | ||||
Covis | DUAKLIR PRESSAIR | aclidinium bromide; formoterol fumarate | POWDER, METERED;INHALATION | 210595-001 | Mar 29, 2019 | RX | Yes | Yes | 8,051,851 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-001 | Jun 26, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Covis | LANOXIN PEDIATRIC | digoxin | INJECTABLE;INJECTION | 009330-004 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Covis | PRILOSEC | omeprazole magnesium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 022056-002 | Mar 20, 2008 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Covis | ALTOPREV | lovastatin | TABLET, EXTENDED RELEASE;ORAL | 021316-002 | Jun 26, 2002 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-002 | Feb 2, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COVIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Covis | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-003 | Jan 10, 2008 | 5,683,677 | ⤷ Sign Up |
Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-003 | Feb 2, 1995 | 4,703,038 | ⤷ Sign Up |
Covis | DUAKLIR PRESSAIR | aclidinium bromide; formoterol fumarate | POWDER, METERED;INHALATION | 210595-001 | Mar 29, 2019 | 7,078,412 | ⤷ Sign Up |
Covis | ZETONNA | ciclesonide | AEROSOL, METERED;NASAL | 202129-001 | Jan 20, 2012 | 5,605,674 | ⤷ Sign Up |
Covis | PRILOSEC | omeprazole magnesium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 022056-002 | Mar 20, 2008 | 5,690,960 | ⤷ Sign Up |
Covis | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-007 | Jan 2, 2008 | 5,626,874 | ⤷ Sign Up |
Covis | DUAKLIR PRESSAIR | aclidinium bromide; formoterol fumarate | POWDER, METERED;INHALATION | 210595-001 | Mar 29, 2019 | 8,129,405 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for COVIS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Tablets | 8.5 mg and 17 mg | ➤ Subscribe | 2009-03-02 |
➤ Subscribe | Injection | 30 mg/mL, 17 mL single-use vials | ➤ Subscribe | 2015-12-04 |
➤ Subscribe | Extended-release Tablets | 20 mg and 30 mg | ➤ Subscribe | 2007-11-07 |
➤ Subscribe | Extended-release Tablets | 40 mg | ➤ Subscribe | 2007-06-11 |
➤ Subscribe | Nasal Spray | 250 mcg | ➤ Subscribe | 2012-02-13 |
➤ Subscribe | Extended-release Tablets | 25.5 mg and 34 mg | ➤ Subscribe | 2008-11-28 |
International Patents for COVIS Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Mexico | 2010008235 | ⤷ Sign Up |
Hungary | 0202100 | ⤷ Sign Up |
Australia | 2009224895 | ⤷ Sign Up |
China | 1997418 | ⤷ Sign Up |
Hong Kong | 1145815 | ⤷ Sign Up |
Poland | 204024 | ⤷ Sign Up |
Singapore | 188825 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for COVIS Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1200431 | C300573 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ACLIDINIUMZOUT MET EEN FARMACEUTISCH AANVAARDBAAR ANION VAN EEN EEN- OF MEERWAARDIG ZUUR, IN HET BIJZONDER ACLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/12/778/001-003EU/1/12/781/001-003 2012200720 |
1200431 | C01200431/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: ACLIDINIUM; REGISTRATION NO/DATE: SWISSMEDIC 62590 25.04.2013 |
0984957 | SPC/GB11/013 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
1200431 | 13C0001 | France | ⤷ Sign Up | PRODUCT NAME: SEL D'ACLIDINIUM AVEC UN ANION PHARMACEUTIQUEMENT ACCEPTABLE D'UN ACIDE MONO OU POLYVALENT, EN PARTICULIER LE BROMURE D'ACLIDINIUM; REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720 |
1200431 | 92132 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: SEL D ACLIDINIUM AVEC ANION D UN ACIDE MONO OU POLYVALENT PHARMACEUTIQUEMENT ACCEPTABLE PARTICULIEREMENT LE BROMURE D ACLIDINIUM |
0984957 | 2012/048 | Ireland | ⤷ Sign Up | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
1411900 | 2011C/016 | Belgium | ⤷ Sign Up | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |